The Midnight Rules Relief Act (HR 115) streamlines Congress's process for disapproving federal regulations issued near the end of a presidential term ("midnight rules"). It allows a single congressional resolution to reject multiple such rules at once, rather than requiring separate votes for each rule, provided the rules were submitted during the final year of a president's term. This directly affects federal agencies that issue these late-issuing regulations and Congress, which gains a more efficient mechanism to block them. The resolution would list each rule by agency and topic, stating they "shall have no force or effect."
This bill (SJRES 122) seeks to block an Environmental Protection Agency (EPA) rule that established procedures for calculating emissions charges on petroleum and natural gas operations, including how companies can net emissions or claim exemptions. It directly affects oil and gas companies that would have been subject to the EPA's new compliance framework. If passed, the resolution would nullify the EPA rule under a specific legal process (chapter 8 of title 5, U.S. Code), preventing it from taking effect. The rule, published November 18, 2024, aimed to streamline how the industry reports and manages emissions-related charges. The resolution does not change the underlying emissions requirements but stops this specific procedural rule from being implemented.
The Good Samaritan Remediation of Abandoned Hardrock Mines Act of 2024 establishes a pilot program allowing qualified individuals or organizations (defined as "Good Samaritans") to remediate historic mine residue at abandoned hardrock mine sites without facing liability for their actions. The Environmental Protection Agency would grant up to 15 permits for projects that address pollution from abandoned mines, with applicants required to demonstrate they meet specific eligibility criteria (not being responsible owners/operators, having no role in creating the residue, and possessing adequate resources). The program includes liability protection for permitted activities, requires detailed remediation plans with baseline condition assessments, public notice, and environmental reviews, and establishes a fund for long-term operations and maintenance. This 7-year pilot program would directly affect communities near abandoned mine sites and qualified remediation groups seeking to address environmental contamination.
HR 10050 requires the Health and Human Services Secretary to study pharmacy benefit manager (PBM) audit practices within one year of enactment. The study will assess financial impacts on independent pharmacies, evaluate if audit deadlines align with medication shelf lives (including FDA-approved 2+ year shelf lives), and examine audit transparency. It will also identify fairer audit processes to reduce burdens on pharmacists while maintaining audit integrity. The report must cover audits for Medicare, Medicaid, and insurance plans, including recommendations for transparency improvements.
The ANTE Act gives the U.S. International Trade Commission (USITC) new authority to investigate whether companies owned by non-market economy countries (like China or Russia, as defined by U.S. trade agencies) are using third countries (e.g., Vietnam or Mexico) to avoid U.S. tariffs on their goods. If the USITC finds evidence of tariff evasion - such as production in a third country to bypass tariffs on goods from a non-market economy - it can recommend trade remedies to the President or Congress. These remedies could include targeted tariffs on the third-country investment or broader import restrictions, requiring Congress to act within 60 days via a joint resolution. The policy would last 3-8 years, with automatic review before expiration to assess if the evasion threat persists. This directly affects companies in non-market economies seeking to circumvent U.S. trade penalties through third-country operations.
The Pharmacists Fight Back Act (HR 9096) sets new rules for Pharmacy Benefits Managers (PBMs) working with federal health care programs like Medicare Part D and Medicaid. It requires PBMs to reimburse in-network pharmacies at a rate covering the drug's actual cost plus a small fee (capped at $25), and to reduce patient cost-sharing by at least 80% of rebates received from drug manufacturers. The bill bans PBMs from steering patients to specific pharmacies, charging patients more than pharmacies are paid, or using rebates to lower pharmacy payments after claims are processed. It also mandates public reporting of drug pricing data to improve transparency, ensuring patients and pharmacies receive fairer treatment under federal health programs.
The PROVE IT Act of 2024 directs the U.S. Energy Secretary to study and publicly report on the greenhouse gas emissions intensity of key U.S. manufactured products (like steel, aluminum, lithium batteries, and critical minerals) compared to those produced in "covered countries" (including the EU, China, and major trading partners). It requires a transparent methodology for calculating emissions data, identifies gaps in existing data, and establishes a public online database showing U.S. emissions advantages for these products. The bill also mandates an annual report on foreign countries using forced labor or human rights abuses in the production of critical minerals or rare earths. Importantly, it clarifies the study does not create new taxes, fees, or mandatory reporting requirements.
The University Accountability Act imposes penalties on tax-exempt universities found in federal court to have violated Title VI of the Civil Rights Act of 1964, requiring them to pay $100,000 or 5% of their administrative compensation per violation. It mandates the IRS to review the tax-exempt status of institutions with more than two such violations and requires these institutions to report civil rights violations on their tax returns. If a violation determination is overturned, the penalty must be refunded. The bill applies to most public and private universities that are tax-exempt under federal law, directly affecting their financial obligations and reporting requirements.
This bill requires Medicare Advantage plans to implement electronic prior authorization systems by 2027 and publish detailed data on their approval and denial rates for medical services by 2026. It directly affects Medicare Advantage plans (private insurers offering Medicare coverage) and their enrollees (seniors 65+), mandating transparency about prior authorization decisions, processing times, and appeal outcomes. Key provisions include requiring plans to report annual statistics on request approvals/denials, average processing times, and use of technology, with this data published publicly by the Centers for Medicare & Medicaid Services. The bill also sets timelines for plan responses to prior authorization requests and mandates reports to Congress on implementation and impacts.
The DETER Act of 2024 requires the President to annually certify whether China violated Taiwan’s sovereignty or territorial integrity (e.g., through sustained economic coercion or military actions). If violations are found, the bill automatically suspends China’s most-favored-nation trade status, triggering higher tariff rates on all Chinese imports. It also mandates a quadrennial assessment of U.S. trade vulnerabilities to China, including economic impacts and mitigation strategies. Congress can temporarily waive these tariffs for one year with fast-track approval, but must review the justification. The bill directly affects U.S. trade policy with China, altering tariff rates based on annual security certifications.
The Court Improvement Program Enhancement Act of 2024 expands federal funding for state court systems to support technological improvements that prevent disruptions (such as natural disasters, cyber-attacks, or public health crises) and enable remote court proceedings. It specifically requires states to assess and implement best practices for remote hearings in foster care and adoption cases, prioritizing participant engagement and privacy during emergencies. The bill mandates that the federal government issue updated guidelines every five years on conducting remote proceedings, with the first guidelines due by January 2025, including consultation with Indian tribes for cases involving Native children under the Indian Child Welfare Act. Additionally, it increases the annual funding reservation for the Court Improvement Program from $30 million to $40 million.
# Summary of Tariff Suspensions and Reductions Document
This document is a section of U.S. tariff legislation that adds new duty suspensions and reductions to the Harmonized Tariff Schedule of the United States. It contains 120 new tariff items (numbered 9902.19.01 through 9902.20.24) that provide temporary duty-free or reduced-duty status for various goods.
Key features of the document:
1. **Content**: The list includes chemical compounds, food ingredients, and specialty materials (such as shelled pine nuts, licorice extract, refined carrageenan, various chemicals like neodymium metal, tungsten concentrate, and numerous organic compounds).
2. **Tariff Treatment**: Most entries are listed as "Free" (meaning duty-free), with a few having small duty rates (e.g., 0.7%, 1.8%, 2.3%, 2.9%, 4.3%).
3. **Effective Period**: All listed suspensions and reductions are effective "On or before 12/31/2025."
4. **Purpose**: These tariff suspensions are intended to support specific industries, reduce costs for manufacturers, or provide temporary relief for certain imported goods.
5. **Technical Details**: Each entry includes the chemical name, CAS number, Harmonized Tariff Schedule code, duty rate, and a brief description of the product.
This document represents a legislative amendment to the Harmonized Tariff Schedule, specifically adding new subchapter II of chapter 99 to provide temporary duty relief for these specific items.
